Comment
Author: Admin | 2025-04-28
Pass into breast milk. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended while using Vyndaqel or Vyndamax.Additional InformationOur Vyndaqel (tafamidis meglumine) Capsules, for Oral Administration and Vyndamax (tafamidis) Capsules, for Oral Administration Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Description for Vyndaqel and VyndamaxVYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) contain tafamidis as the active moiety, which is a selective stabilizer of transthyretin.The chemical name of tafamidis meglumine is 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid mono (1-deoxy-1-methylamino-D-glucitol). The molecular formula is C14H7Cl2NO3 C7H17NO5, and the molecular weight is 503.33 g/mol. The structural formula is:Tafamidis meglumine 20-mg soft gelatin capsule for oral use contains a white to pink colored suspension of tafamidis meglumine 20 mg (equivalent to 12.2 mg of tafamidis free acid), and the following inactive ingredients: ammonium hydroxide 28%, brilliant blue FCF, carmine, ethyl alcohol, gelatin, glycerin, iron oxide (yellow), isopropyl alcohol, polyethylene glycol 400, polysorbate 80, polyvinyl acetate phthalate, propylene glycol, purified water, sorbitan monooleate, sorbitol, and titanium dioxide.The chemical name of tafamidis is 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid. The molecular formula is C14H7Cl2NO3, and the molecular weight is 308.12 g/mol. The structural formula is:Tafamidis 61-mg soft gelatin capsule for oral use contains a white to pink colored suspension of tafamidis 61 mg and the following inactive ingredients: ammonium hydroxide 28%, butylated hydroxytoluene, ethyl alcohol, gelatin, glycerin, iron oxide (red), isopropyl alcohol, polyethylene glycol 400, polysorbate 20, povidone (K-value 90), polyvinyl acetate phthalate, propylene glycol, purified water, sorbitol, and titanium dioxide. Uses for Vyndaqel and VyndamaxVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Dosage for Vyndaqel and VyndamaxRecommended DosageThe recommended dosage is either VYNDAQEL 80 mg (four 20-mg
Add Comment